Tivic health enters gmp manufacturing validation agreement with scorpius biomanufacturing in preparation for fda submission

Fremont, calif.--(business wire)--tivic health® systems, inc. (nasdaq: tivc), a diversified therapeutics company, announced today it has entered a definitive agreement with scorpius biomanufacturing to complete the gmp manufacturing validation of the lead candidate from its tlr5 program, entolimod™, for treatment of acute radiation syndrome, or ars, in preparation for filing a biological licensing application, or bla, with the u.s. food & drug administration. scorpius biomanufacturing, inc.
TIVC Ratings Summary
TIVC Quant Ranking